# A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

> **NCT02227784** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 366 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Evacetrapib
- **DRUG:** Atorvastatin
- **DRUG:** Ezetimibe
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02227784
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 366 (ACTUAL)
- **Why stopped:** Study termination due to program termination.
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227784, "A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02227784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*